Anifrolumab in Systemic Lupus Erythematosus With Severe Hematological Manifestations: A Spanish Multicenter Study
J Rheumatol 2025; doi: 10.3899/jrheum.2025-0658 In the 4th paragraph regarding severe hematological involvement, the criterion for severe leukopenia should be a leukocyte count of < 2 × 10<sup>9</sup>/L. The revised text is "severe leukopenia (leukocyte count < 2 × 10<sup>9</sup>/L)." This correction applies only to the October 1 First Release. The correct text appears in the print and online issues.
Authors
- Santos Castañeda (ORCID: https://orcid.org/0000-0002-7748-853X)
- Vanesa Calvo-Río (ORCID: https://orcid.org/0000-0002-9654-0698)
- Marta Garijo-Bufort (ORCID: https://orcid.org/0000-0003-0286-0955)
- Juan José Alegre Sancho (ORCID: https://orcid.org/0000-0003-1641-0875)
- Miriam Retuerto (ORCID: https://orcid.org/0000-0003-0248-657X)
- A. Mayo-Juanatey (ORCID: https://orcid.org/0009-0008-5434-3021)
- Manuel Olivares (ORCID: https://orcid.org/0000-0001-6637-3553)
Institutions
- Marqués de Valdecilla University Hospital (ES)
- Hospital Universitario Doctor Peset (ES)
- Hospital Universitario de La Princesa (ES)
- Hospital de Sagunto (ES)
- Complejo Asistencial Universitario de Palencia (ES)
- Hospital Universitario Infanta Cristina (ES)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.3899/jrheum.2025-0658.c1
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00